The Association Between Serum Vitamin D Level and Efficacy of Nivolumab Treatment in Patients with Advanced NSCLC
Abstract views: 68
/ 
PDF downloads: 38
DOI:
https://doi.org/10.5281/zenodo.8402529Keywords:
25-hydroxy vitamin D, Nivolumab, Non–small cell lung cancerAbstract
Objective: Vitamin D is known to be associated with better responses and prognosis positively proportional to serum levels in patients with non–small cell lung cancer (NSCLC). The goal of this report was to examine the association between serum Vitamin D levels and efficacy of Nivolumab treatment in patients with metastatic NSCLC.
Methods: A total of 38 patients with a diagnosis of metastatic NSCLC, received Nivolumab immunotherapy in the second-line therapy were enrolled in the study. Clinical and demographic data and also the levels of 25 hydroxy vitamin D (25(OH)D) that were analyzed before starting Nivolumab treatment were recorded. The association between the vitamin D and progression free survival (PFS) and overall survival (OS) was analyzed. Statistical evaluation was done using SPSS 23.
Results: The median 25(OH)D level of the patients was found as 17.3 (3-37) ng/ml. When the PFS of patients were evaluated according to vitamin D status, PFS of the patients with 25(OH)D ≥20 ng/ml was longer than other groups that was not significant (p= 0.17).
Conclusion: Achievement longer PFS with sufficient vitamin D supports the fact that higher baseline vitamin D levels are associated with better Nivolumab efficacy in metastatic NSCLC patients.
References
Akiba, T., Morikawa, T., Odaka, M., Nakada, T., Kamiya, N., Yamashita, M.,… Urashima, M. (2018). Vitamin d supplementation and survival of patients with non-small cell lung cancer: a randomized, double-blind, placebo-controlled trial. Clin Cancer Res an Off J Am Assoc Cancer Res 24(17):4089–4097.
Alsaab, H.O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S.K., Iyer, A.K. (2017). PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front. Pharm., 8, 561.
Bochen, F., Balensiefer, B., Korner, S., Bittenbring, J.T., Neumann, F., Koch, A.,…Linxweiler, M. (2018). Vitamin D deficiency in head and neck cancer patients-prevalence, prognostic value and impact on immune function. Oncoimmunology, 7, e1476817.
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E.,...Brahmer, J.R. (2015). Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med; 373: 1627–1639.
Boussiotis V.A. (2016). Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med ; 375:1767–1778.
Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E.,... Spigel, D.R. (2015). Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N. Engl. J. Med. 373, 123–135.
Castellano-Castillo, D., Morcillo, S., Clemente-Postigo, M., Crujeiras, A.B., Fernandez-García, J.C., Torres, E.,… Macias-Gonzalez, M. (2018). Adipose tissue inflammation and VDR expression and methylation in colorectal cancer. Clin Epigenetics 10:60.
Cusato J, Genova C, Tomasello C, Carrega P, Ottonello S, Pietra G,… D’Avolio, A.(2019) Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers. 11(1):125.
Dimitrov, V., Bouttier, D., Boukhaled, G., Salehi-Tabar, R., Avramescu, R.G., Memari, B.,...White, J.H. (2017) Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice. J Biol Chem 292(50):20657–20668.
Feng, Q., Zhang, H., Dong, Z., Zhou, Y., Ma, J. (2017). Circulating 25-hydroxyvitamin D and lung cancer risk and survival: A dose-response meta-analysis of prospective cohort studies. Medicine (Baltimore) , 96, e8613.
Gettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M.,…Brahmer J. (2018). Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 36:1675–1684.
Hendrickson, W.K., Flavin, R., Kasperzyk, J.L., Fiorentino, M., Fang, F., Lis, R.,… Giovannucci, E. (2011). Vitamin d receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol Off J Am Soc Clin Oncol. 29(17):2378–2385.
Herbst, R.S., Baas, P., Kim, D-W., Felip, E., Pérez-Gracia, J.L., Han, J-Y.,... Garon, E.B. (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 387; 1540–1550
Khan, M., Lin, J., Liao, G., Tian, Y., Liang, Y., Li, R.,…Yuan, Y. (2018) Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Medicine (Baltimore), 97, e11936.
Kim, S.H., Chen, G., King, A.N. Jeon, C.K. Christensen, P.J., Zhao, L.,...Ramnath, N. (2012) Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer 77(2):265–271
Liu, S.Y.M., Zheng, M.M., Pan, Y., Liu, S.Y., Li, Y., Wu, Y.L. (2023). Emerging evidence and treatment paradigm of non-small cell lung cancer. J Hematol Oncol 16, 40.
Menezes, R.J., Cheney, R.T., Husain, A., Tretiakova, M., Loewen, G., Johnson, C.S.,...Reid, M.E. (2008) Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Prev Biomarkers 17(5):1104–1110
Ness, R.A., Miller, D.D., Wei, L. (2015) The role of vitamin D in cancer prevention. Chin J Nat Med 13(7):481–497.
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A.,…Brahmer JR. (2021). Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol. 39:2339–2349.
Reck, M., Remon, J., Hellman, M.D. (2022). First-line immunotherapy for non–small-cell lung cancer. Journal of Clinical Oncology, 40.6: 586-597.
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., Pawel, J.v.,…Gandara, D.R. (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255–265.
Ross, A.C., Taylor, C.L., Yaktine, A.L., Valle. H.B.D. eds. Dietary Reference Intakes for Calcium and Vitamin D. National Academies Press (US); 2011. Institute of Medicine. Committee to Review Dietary Reference Intakes for Vitamin D, Calcium. The National Academies Collection: Reports funded by National Institutes of Health.
Samet, J.M., Avila-Tang, E., Boffetta, P., Hannan, L.M., Olivo-Marston, S., Thun, M.J., Rudin, C.M. (2009). Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clinical Cancer Research, 15(18), 5626-5645.
Singh, R.K., Kim, K., Rowswell-Turner, R.B., Hansen, J.N., Khazan, N., Jones, A.,…Moore, R.G. (2020) Targeting Vitamin-D receptor (VDR) by a small molecule antagonist MeTC7 inhibits PD-L1 but controls THMYCN neuroblastoma growth PD-L1 independently. bioRxiv, 2020.08. 16.252940.
Socinski, M.A., Jotte, R.M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N.,...Reck, M. (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301.
Spigel, D.R., Faivre-Finn, C., Gray, J.E., Vicente, D., Planchard, D., Paz-Ares, L.,…Antonia, S.J. (2022). Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 40:1301–1311.
Tykodi, S.S, Schadendorf, D., Cella, D., Reck, M., Harrington, K., Wagner, S., Shaw, J.W. (2018) Patient-reported outcomes with nivolumab in advanced solid cancers. Cancer Treat. Rev., 70, 75–87.
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H.J.,...Cappuzzo, F. (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 924–937.
You, W., Liu, X., Tang, H., Lu, B., Zhou, Q., Li, Y.,…Tan B. (2023). Vitamin D Status Is Associated With Immune Checkpoint Inhibitor Efficacy and Immune-related Adverse Event Severity in Lung Cancer Patients: A Prospective Cohort Study. Journal of Immunotherapy, 46(6), 236-243.
Zhou, W., Suk, R., Liu, G., Park, S., Neuberg, D.S., Wain, J.C.,… Christiani, D.C. (2005) Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomark Prevent. 14(10):2303–2309.
Zhou, W., Heist, R.S., Liu, G., Asomaning, K., Neuberg, D.S., Hollis, B.W.,… Christiani, D.C. (2007). Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol. 25(5):479–485.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 GEVHER NESIBE JOURNAL OF MEDICAL AND HEALTH SCIENCES
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The journal is licensed under a 